Glycolysis and Bone Formation: From Pathological Mechanisms to Regulatory Strategies
Cell Biochemistry and Function · 2026-11 · 44 (11)
DOI: 10.1002/cbf.70341 ↗Abstract
ABSTRACT Bone homeostasis is maintained by the balance between osteoblast‐mediated bone formation and osteoclast‐induced bone resorption, and reduced osteoblastic activity contributes to osteoporosis (OP) and other bone disorders. Energy metabolism, especially glycolysis, has emerged as a critical regulator of osteoblast function and bone formation, yet its integrated role in physiological and pathological bone metabolism remains to be systematically defined. Here, we summarize the multi‐faceted mechanisms by which glycolysis modulates bone formation: glucose metabolic shifts during osteoblast differentiation, provision of energy substrates and metabolic intermediates for osteoblastic activities, regulation of glycolytic enzyme expression via key signaling pathways (e.g., Wnt) and transcription factors (HIF‐1α, mTOR), and mediation of metabolism‐differentiation crosstalk by non‐coding RNAs, including microRNAs (miRNAs) and lncRNAs, through targeted glycolytic gene regulation. In OP, glycolytic remodeling exacerbates impaired bone formation, and targeting pivotal glycolytic nodes for metabolic reprogramming holds great promise for developing novel osteoanabolic therapies against bone diseases. Significance Statement Bone formation is an energy‐intensive process, yet the vital role of glycolysis in driving osteoblast function is often underestimated. This review elucidates how glucose metabolism fuels bone formation, serving not only as an energy source but also as a critical regulator of cell differentiation. We synthesize evidence linking specific metabolic enzymes and signaling networks to skeletal health and demonstrate how these pathways are disrupted in diseases like osteoporosis. This work is important because it establishes a clear framework connecting cellular metabolism to bone pathology. By identifying key metabolic nodes as therapeutic targets, we offer a roadmap for developing novel strategies to treat bone disorders through metabolic reprogramming.
EUVIMED